Dr. Kris Chavatte
Angestellt, European Sales Director Medical Devices, Alphatec Spine
Kuesnacht, Schweiz
Werdegang
Berufserfahrung von Kris Chavatte
Bis heute 13 Jahre und 2 Monate, seit Apr. 2011
European Sales Director Medical Devices
Alphatec Spine
Sales Director for distribution markets for Alphatec Spine and ScientX in Europe including Israel and Russia with exceptance for DACH. Business development, growth, identify new markets
3 Jahre und 6 Monate, Sep. 2007 - Feb. 2011
Senior Product Director Spine Augmentation Europe
Synthes GmbH Switzerland
Develop and market introduction of new spinal augmentation solutions in Europe. PMDA product registration for the Japanese market.
1 Jahr und 4 Monate, Feb. 2006 - Mai 2007
Sales & Marketing Director
AFT GmbH Germany
Sales and Marketing director - 80% automotive industry (conveyor technology), 20% non-automotive including pharmaceuticals, white goods, food and drinks
3 Jahre und 2 Monate, Jan. 2003 - Feb. 2006
Product Director EMEA
Tyco Healthcare (Covidien) EMEA
Medical Technology, investment goods - spine business - electrosurgery business. Responsible for sales region respresenting 68 Mio Euro turn-over - Tyco award best sales increase 2006. Recovery plan manager for Germany, Austria and Switzerland. Covering B, Nl, D, A, CH, Scandinavia, PL, Cz, Rus, Slo, Cro, Ser, Middle East.
2 Jahre und 7 Monate, Juni 2000 - Dez. 2002
Project Manager Spin Off MedarA
SCKCEN
Lead start-up CIE MedarA (Medical Application for Radiation), a spinoff from the Belgian institute for nuclear research SCK CEN. Aimed at the commercialisation of a radioisotope generator system for medical application in radiodiagnosis and radiotherapy (oncology)
Ausbildung von Kris Chavatte
1 Jahr und 10 Monate, Sep. 2002 - Juni 2004
Business Administration
Antwerp University Business School
3 Jahre und 11 Monate, Sep. 1996 - Juli 2000
Medical Sciences, Nuclear Medicine
Vrije Universiteit Brussels
Development of Radiopharmaceuticals derived from Neurotensin, Bombesin and Somatostine labelled with Tc-99m, Re-188, I-123, I-131. F-18 for diagnosis in targeted radiotherapy.
4 Jahre und 10 Monate, Sep. 1991 - Juni 1996
Radiopharmaceutical Chemistry
Vrije Universiteit Brussels
alpha.-methyl I-123 Tyrosine and analogue labelled amino acids
Sprachen
Niederländisch
Muttersprache
Englisch
Fließend
Deutsch
Fließend
Französisch
Fließend
Portugiesisch
Grundlagen